AxoGen, Inc. (NASDAQ:AXGN) Shares Purchased by Bradley Foster & Sargent Inc. CT

Bradley Foster & Sargent Inc. CT raised its position in AxoGen, Inc. (NASDAQ:AXGN) by 3.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,153 shares of the medical equipment provider’s stock after purchasing an additional 2,989 shares during the quarter. Bradley Foster & Sargent Inc. CT owned 0.19% of AxoGen worth $1,387,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of AXGN. Quest Partners LLC raised its holdings in shares of AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 2,076 shares during the period. R Squared Ltd purchased a new stake in shares of AxoGen during the 4th quarter valued at about $30,000. Oppenheimer & Co. Inc. purchased a new stake in shares of AxoGen during the 3rd quarter valued at about $156,000. Quantbot Technologies LP purchased a new stake in shares of AxoGen during the 3rd quarter valued at about $165,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of AxoGen by 238.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider’s stock valued at $172,000 after buying an additional 8,656 shares during the period. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

AxoGen Price Performance

AXGN stock opened at $18.00 on Friday. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. AxoGen, Inc. has a 52-week low of $5.55 and a 52-week high of $19.19. The stock’s 50 day moving average is $17.29 and its two-hundred day moving average is $14.77. The company has a market capitalization of $792.18 million, a PE ratio of -56.25 and a beta of 1.00.

Analyst Ratings Changes

Separately, Canaccord Genuity Group raised their target price on AxoGen from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, February 3rd.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.